D. Boral Capital Reaffirms “Buy” Rating for Enlivex Therapeutics (NASDAQ:ENLV)

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a research report issued on Friday,Benzinga reports. They presently have a $13.00 price target on the stock.

Enlivex Therapeutics Stock Performance

ENLV opened at $1.03 on Friday. The stock has a market capitalization of $22.05 million, a price-to-earnings ratio of -1.05 and a beta of 0.99. The company has a fifty day moving average of $1.18 and a 200 day moving average of $1.29. Enlivex Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $4.59.

Enlivex Therapeutics (NASDAQ:ENLV) last released its quarterly earnings results on Friday, November 29th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.04. On average, equities research analysts forecast that Enlivex Therapeutics will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Enlivex Therapeutics

A hedge fund recently bought a new stake in Enlivex Therapeutics stock. Sigma Investment Counselors Inc. bought a new stake in shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 30,000 shares of the company’s stock, valued at approximately $50,000. Sigma Investment Counselors Inc. owned 0.14% of Enlivex Therapeutics at the end of the most recent quarter. 1.02% of the stock is owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.